Related Experiment Video
Updated: Aug 13, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Joint Risk Factor Combinations with Additive Interaction Increase the Risk of Parkinson's Disease
Andrea Quattrone1,2, Basilio Vescio2, Fulvia Arcuri2
1Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.
Summary
Joint risk factors significantly increase late-onset Parkinson's disease (LOPD) risk. Modifiable factors like loneliness and low handgrip strength are key contributors, suggesting targeted prevention can reduce LOPD incidence.
Area of Science:
- Neuroscience
- Epidemiology
- Public Health
Background:
- The combined impact of multiple risk factors on late-onset Parkinson's disease (LOPD) is not well understood.
- Characterizing these combined effects is crucial for effective prevention strategies.
Purpose of the Study:
- To quantify the impact of joint risk exposures on incident LOPD.
- To estimate the contribution of potentially modifiable factors to LOPD risk.
Main Methods:
- A prospective cohort study of 311,261 UK Biobank participants aged 50+ followed for up to 15 years.
- Multivariable Cox models assessed 65 risk factors; additive interactions were evaluated for pairs and triplets.
- Population-attributable fractions estimated for modifiable risk factors.
Main Results:
- Eighteen risk factors independently associated with LOPD; joint exposures (pairs/triplets) showed significantly larger effect sizes.
- Loneliness, low handgrip strength, epilepsy, hearing loss, and diabetes were key modifiable contributors in high-risk combinations.
- Removing modifiable factors from additive pairs/triplets reduced mean HRs by 30%/49%; population-level reduction in LOPD incidence was estimated at 34.4%.
Conclusions:
- Integrating single-factor analysis with joint exposure profiles can improve LOPD risk stratification.
- Targeted prevention strategies focusing on modifiable risk factors are essential for reducing LOPD incidence.
Related Concept Videos
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...